|Bid||265.01 x 800|
|Ask||267.40 x 1400|
|Day's Range||266.88 - 272.73|
|52 Week Range||165.23 - 306.08|
|Beta (5Y Monthly)||0.88|
|PE Ratio (TTM)||33.72|
|Earnings Date||Oct 28, 2020 - Nov 02, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||306.04|
Here's a simple argument for why long-term investors should consider buying shares of biotech companies. Since its inception in 2006, the SPDR S&P Biotech Index -- an industry benchmark -- has crushed the S&P 500, as the graph below shows. This graph doesn't show us the specific biotech stocks that performed well throughout this period, and we can't assume the trend will continue indefinitely; after all, the market is forward-looking.
People across the world increased their online buying during the coronavirus-related lockdowns. As the largest e-commerce retailer in the world, Amazon was a prime beneficiary. The convenience of shopping online, combined with continued worries about COVID-19, should keep Amazon's sales momentum going even if the recession continues for a much longer period.
Vertex (VRTX) raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading.